Investigational drug · Phase 3
HRS-7535
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
3 still active
All registered trials
20
Any phase or sponsor naming "HRS-7535"
First trial start
2024
Feb 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-7535", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
- Chronic Kidney Disease
- Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- Hypertension With Overweight or Obesity
- Diabetic Kidney Disease, Type 2 Diabetes
- Chronic Weight Management
- Overweight and Obesity
- Overweight or Obesity
- Overweight
- Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · High blood pressure (hypertension) · Heart failure · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-7535" as an intervention, largest first.
- Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney DiseasePivotal-lookingNot yet recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07625774 · 3,690 participants (planned) · Start Jul 2026 · Primary completion May 2031
Drug: HRS-7535; Placebo · For: Chronic Kidney Disease
Sites: Tianjin, China; Hangzhou, China
- A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With MetforminPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06589765 · 810 participants · Start Sep 27, 2024 · Primary completion May 29, 2026
Drug: HRS-7535 tablet; dapagliflozin tablet · For: Type 2 Diabetes
Sites: Beijing, China
- Phase III Study of HRS-7535 for Hypertension With Overweight or ObesityPivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07528027 · 648 participants (planned) · Start May 29, 2026 · Primary completion Dec 2027
Drug: HRS-7535; Placebo · For: Hypertension With Overweight or Obesity
Sites: Beijing, China; Harbin, China
- A Trial of HRS-7535 Tablets in Subjects With Overweight or ObesityPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06904105 · 556 participants · Start Apr 10, 2025 · Primary completion Apr 17, 2026
Drug: HRS-7535 Tablets; HRS-7535 Placebo Tablets · For: Overweight; Obesity
Sites: Beijing, China
- A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and ExercisePivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06672172 · 284 participants · Start Sep 25, 2024 · Primary completion Nov 13, 2025
Drug: HRS-7535 tablet; HRS-7535 tablet and 2 more · For: Type 2 Diabetes
Sites: Beijing, China
- Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 DiabetesPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06415214 · 281 participants · Start Jun 21, 2024 · Primary completion Jul 15, 2025
Drug: Placebo; HRS-7535 · For: Diabetic Kidney Disease, Type 2 Diabetes
Sites: Hangzhou, China
- Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .Pivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06250946 · 235 participants · Start Feb 23, 2024 · Primary completion Jan 22, 2025
Drug: HRS-7535;Placebo; Placebo · For: Overweight and Obesity
Sites: Beijing, China
- Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and ObesityPivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06820099 · 225 participants (planned) · Start Apr 10, 2025 · Primary completion Dec 2026
Drug: HRS-7535 tablet; HRS-7535 tablet placebo · For: Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Sites: Beijing, China
- A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes MellitusPivotal-lookingStatus unknown
Shandong Suncadia Medicine Co., Ltd.Industry
NCT05759897 · 180 participants (planned) · Start Feb 28, 2023 · Primary completion Dec 21, 2023
Drug: HRS-7535; Placebo · For: Type 2 Diabetes
- Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.Pivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06393348 · 155 participants · Start May 17, 2024 · Primary completion Nov 15, 2024
Drug: HRS-7535; Placebo · For: Type 2 Diabetes
Sites: Guangdong, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of HRS-7535, a novel oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes mellitus inadequately controlled by metformin and sodium-glucose co-transporter 2 inhibitors: a multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase II trial.
Xu M, Song W, Lv F, et al. · Diabetologia 2026
- Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lv R, Peng L, Xu Y, et al. · EClinicalMedicine 2026
- HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.
Gu W, Zhang L, Li L, et al. · Nat Commun 2026
- HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.
Guo L, Sun Z, Zhang L, et al. · JAMA Netw Open 2026
- Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
Wu J, Zhou R, Zhang Q, et al. · Diabetes Obes Metab 2024
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- HDM1005Phase 35 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Obstructive Sleep Apnea (OSA) and Obesity, Obesity, Type 2 Diabetes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.